Dental and medical products company Henry Schein (NASDAQ:HSIC) announced better-than-expected revenue in Q1 CY2026, with sales up 6.3% year on year to $3.37 ...
Dental and medical products company Henry Schein (NASDAQ:HSIC) will be reporting results this Tuesday before market open. Here’s what to expect. Henry Schein...
Looking back on dental equipment & technology stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including Envista (NYSE:NVST) and its...
The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer. However, the challenge lies in determining whether t...
Over the past six months, Henry Schein has been a great trade, beating the S&P 500 by 17.3%. Its stock price has climbed to $75.99, representing a healthy 19...
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Players catalyzing medical advanceme...
The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning. Some companies face significant ch...
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking a...
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. Not...
Even if a company is profitable, it doesn’t always mean it’s a great investment.
Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential.
Shares of dental and medical products company Henry Schein (NASDAQ:HSIC)
jumped 4.8% in the afternoon session after the company reported decent fourth-quarter 2025 financial results where revenue surpassed Wall Street's expectations, but earnings fell short. The dental and medical products distributor posted quarterly sales of $3.44 billion, a 7.7% increase year on year that beat analyst forecasts. Investors appeared to focus on the strong top-line performance, which was supported by a 4.9% rise in organic revenue. However, the results were not entirely positive, as the company's GAAP profit of $0.85 per share missed Wall Street's consensus estimates by 16.4%. Overall, the market's positive reaction suggests that the better-than-expected sales outweighed the disappointment from the earnings miss for the quarter.
Dental and medical products company Henry Schein (NASDAQ:HSIC) reported Q4 CY2025 results beating Wall Street’s revenue expectations, with sales up 7.7% year on year to $3.44 billion. Its GAAP profit of $0.85 per share was 16.4% below analysts’ consensus estimates.
Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets.
